Just a short note.........for "Investors" only!
With its current market valuation of $220Million, Exicure, Inc. is set to declare its quarterly results on November 12, 2020. XCUR Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.1 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.25 for 2021 with estimates of that growing to -$0.49 in next year. These estimates are suggesting current year growth of -0.46% for EPS and 0.96% growth next year.
In contrast, when we review XCUR stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 5 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Exicure, Inc. (XCUR) as a Hold, while 5 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the XCUR stock which is currently positioned at 0. It further provides that stock’s current price level is 12.29% away from its 20-day simple moving average and is 30.24% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 62.72 while volatility remained at 9.61% over the past week which changes to 9.75% when measuring it over the past month. Beta is valued at 0, while measure of average true range or ATR is currently at 0.21. In predicting price targets of as low as $6 and as high as $18, analysts are in agreement on assigning the stock over the next 12 months average price target of $10. Stock’s current price level is 157.51% above from estimated low price target while it is 672.53% below the estimated high; and even if the XCUR’s share succeeded to reach the median price of $8, then the outlook of +243.35% could come to the excitement of the investors.
In comparing Exicure, Inc. (XCUR)’s stock with other industry players reveals that stock’s current price change of +0.87% and that of -11.41% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 0.58% in the last trading and went through an increase of 7.85% in past 12-month trading. Industry’s another major player Bristol-Myers Squibb Company (BMY) has jumped 0.59% up in previous session, but over the past year has faced a fall of -3.45%, while Gilead Sciences Inc (GILD) was also up 0.87% however its price remained floating in the red at -11.41% over the same period. Exicure, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 20.44 while Bristol-Myers Squibb Company is showing 0 for the same. On the other hand, the S&P 500 Index was down -0.3% in the last trading session while the Dow Jones Industrial closed the session lower at -0.57%.
Having a second look at Exicure, Inc. (NASDAQ:XCUR) provides that stock’s average daily trading volume for 3 months was 466.23 Million, while it jumped to 604.01 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 87.6 Million.
_____________________
With its current market valuation of $220Million, Exicure, Inc. is set to declare its quarterly results on November 12, 2020. XCUR Stock’s Forward Dividend of 0 and its yield of 0% are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.1 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.25 for 2021 with estimates of that growing to -$0.49 in next year. These estimates are suggesting current year growth of -0.46% for EPS and 0.96% growth next year.
In contrast, when we review XCUR stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 5 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending Exicure, Inc. (XCUR) as a Hold, while 5 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the XCUR stock which is currently positioned at 0. It further provides that stock’s current price level is 12.29% away from its 20-day simple moving average and is 30.24% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 62.72 while volatility remained at 9.61% over the past week which changes to 9.75% when measuring it over the past month. Beta is valued at 0, while measure of average true range or ATR is currently at 0.21. In predicting price targets of as low as $6 and as high as $18, analysts are in agreement on assigning the stock over the next 12 months average price target of $10. Stock’s current price level is 157.51% above from estimated low price target while it is 672.53% below the estimated high; and even if the XCUR’s share succeeded to reach the median price of $8, then the outlook of +243.35% could come to the excitement of the investors.
In comparing Exicure, Inc. (XCUR)’s stock with other industry players reveals that stock’s current price change of +0.87% and that of -11.41% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price raised by 0.58% in the last trading and went through an increase of 7.85% in past 12-month trading. Industry’s another major player Bristol-Myers Squibb Company (BMY) has jumped 0.59% up in previous session, but over the past year has faced a fall of -3.45%, while Gilead Sciences Inc (GILD) was also up 0.87% however its price remained floating in the red at -11.41% over the same period. Exicure, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 20.44 while Bristol-Myers Squibb Company is showing 0 for the same. On the other hand, the S&P 500 Index was down -0.3% in the last trading session while the Dow Jones Industrial closed the session lower at -0.57%.
Having a second look at Exicure, Inc. (NASDAQ:XCUR) provides that stock’s average daily trading volume for 3 months was 466.23 Million, while it jumped to 604.01 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 87.6 Million.
_____________________
